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Objectives: Antibiotic resistance has risen dramatically
over the past years. For individual patients, adequate
initial antibiotic therapy is essential for clinical outcome.
Computer-assisted decision support systems (CDSSs)
are advocated to support implementation of rational
anti-infective treatment strategies based on guidelines.
The aim of this study was to evaluate long-term effects
after implementation of a CDSS.
Design: This prospective ‘before/after’ cohort study was
conducted over four observation periods within 5 years.
One preinterventional period (pre) was compared with
three postinterventional periods: directly after intensive
implementation efforts (post1), 2 years (post2) and
3 years (post3) after implementation.
Setting: Five anaesthesiological-managed intensive care
units (ICU) (one cardiosurgical, one neurosurgical, two
interdisciplinary and one intermediate care) at a
university hospital.
Participants: Adult patients with an ICU stay of >48 h
were included in the analysis. 1316 patients were
included in the analysis for a total of 12 965 ICU days.
Intervention: Implementation of a CDSS.
Outcome measures: The primary end point was
percentage of days with guideline adherence during ICU
treatment. Secondary end points were antibiotic-free
days and all-cause mortality compared for patients with
low versus high guideline adherence.
Main results: Adherence to guidelines increased from
61% prior to implementation to 92% in post1,
decreased in post2 to 76% and remained significantly
higher compared with baseline in post3, with 71%
(p=0.178). Additionally, antibiotic-free days increased
over study periods. At all time periods, mortality for
patients with low guideline adherence was higher with
12.3% versus 8% (p=0.014) and an adjusted OR of
1.56 (95% CI 1.05 to 2.31).
Conclusions: Implementation of computerised regional
adapted guidelines for antibiotic therapy is paralleled
with improved adherence. Even without further
measures, adherence stayed high for a longer period
and was paralleled by reduced antibiotic exposure.
Improved guideline adherence was associated with
reduced ICU mortality.
Trial registration number: ISRCTN54598675.
INTRODUCTION
The use of antibiotics in medicine, which has
led to the emergence and dissemination of
resistant pathogens,1 2 has major implications
for morbidity and mortality in intensive care
units (ICUs).3 Early adequate therapy is
crucial for the outcome of critically ill
patients.4 5 Moreover, it has implications for
healthcare costs.6 Despite this, the rate of
inappropriate antibiotic usage remains high.7
Barriers to change management have been
identiﬁed in different healthcare settings.
However, although intensive efforts have
demonstrated some potential to improve
practice, longer-term follow-up has failed to
show sustained effects.8 Reasons for delays in
initiating adequate therapy include the lack of
availability of information and difﬁculties with
prompt prescribing typically due to inefﬁcient
communication between staff members. On
the other hand, initiating and performing
microbiological diagnostics is also challenging,
Strengths and limitations of this study
▪ No previous study has examined the possible
long-term effect of a computerised decision
support system for antibiotics on adherence to
locally adapted guidelines developed by a multi-
disciplinary team.
▪ The results suggest that adherence to locally
adapted guidelines increased following imple-
mentation of a computerised decision support
system and remained at a reasonable level.
▪ This was paralleled by an increase of antibiotic-
free days and lower mortality was observed in
patients with high guideline adherence.
▪ Data from this study are based mainly on surgi-
cal patients in one university hospital; conse-
quently, external validity is restricted mainly to
the postoperative setting and we do not know
whether our findings are reliable for other facil-
ities. The unblinded nature and non-randomised
design are further study limitations.
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but there is evidence that a less aggressive treatment
strategy might be beneﬁcial for patient outcomes as long
as expedient microbiology is available.9 For this reason,
experts from all over the world have encouraged the
development of stewardship programmes as a major
goal for the future.10 11 Although locally adapted guide-
lines may help to enhance microbiological diagnostics
and initial antibiotic therapy, these are not always readily
available. Thus, computerised decision support systems
(CDSSs) have been developed and studied over the past
several years.12 13 In the 1990s, Evans et al13 developed a
system for antimicrobial therapy and were able to show a
reduction in inpatient costs and length of stay. Buising
et al14 were able to show that, as an educational
measure, a CDSS was the single most efﬁcient method
of improving guideline implementation for the treat-
ment of community-acquired pneumonia compared
with education alone.
However, there is currently no evidence regarding the
long-term efﬁcacy of a CDSS to improve guideline
adherence to the treatment of the most relevant infec-
tions in a surgical ICU setting. For this study we hypothe-
sised that implementation of a CDSS for antibiotic
therapy, speciﬁcally one created by a multidisciplinary
front-line team, is able to increase and maintain guide-
line adherence without further efforts. Presumably, this
should lead to decreased antibiotic usage and improved
clinical outcome.
MATERIAL AND METHODS
This prospective cohort study was conducted as a clinical
prospective prentervention/postintervention study over
four evaluation time periods within 5 years totalling
12 965 patient days in the ICU. The preinterventional
period (‘pre’) took place from January to April 2006,
the ﬁrst postinterventional period (‘post1’) from
February to April 2007, post2 from August to October
2009 and post3 from February to March 2010.
During the pre-period, paper-based guidelines for
antibiotic therapy were made available to every ward
physician. Guidelines incorporated national and inter-
national guidelines for diagnostics as well as for therapy
and were adjusted to the institutional resistances rates.
These paper-based guidelines contained a short deﬁn-
ition, diagnostic requirements, the spectrum of causative
pathogens and empiric therapy recommendations for
every infection.
Following this baseline time period, a CDSS for anti-
biotic therapy was designed as a tool to provide clini-
cians with essential guideline-based information
concerning the treatment of infections, the use of anti-
biotic agents and microbiological diagnostics in the
ICU. The CDSS could be accessed from every computer
in the hospital, including all computers used to docu-
ment electronic patient ﬁles. The CDSS contains algo-
rithms and pathways for most infections occurring in
patients in surgical ICUs. For every infection included in
the CDSS, there is one main ﬁve step algorithm. This
algorithm leads the user to the ﬁrst interface to reassess
infection signs to evaluate whether diagnosis of an infec-
tion is plausible. Next, the user is guided to a page
where the suspected infection focus has to be identiﬁed.
Then, there is a request for differential diagnoses and
focus speciﬁcations, followed by a fourth page showing
diagnostic procedures that are needed for the speciﬁc
focus. In the ﬁfth step there is a page where suggestions
are made for empiric therapy (compare ﬁgure 1A).
Additionally, the CDSS includes links to references and
background information focusing on the infections
covered and also points out the tools required, for
example, calculators for renal creatinine clearance.
Local resistance patterns of bacterial pathogens were
included for every study ward (compare ﬁgure 1B–C).
Each algorithm was developed by a multidisciplinary
team of ICU experts from the ﬁelds of microbiology,
infectious diseases, surgery, pharmacology and specia-
lists for each focus of the algorithms. The team
also included front-line providers of patient care and
those with less professional experience (residents and
medical students).
The CDSS also contains a section for bacterial patho-
gens and their targeted treatment (compare ﬁgure 1B).
In patients with microbiological pathogen identiﬁcation
the CDSS can be used to guide choice of targeted anti-
biotic therapy as well. In summary, the programme was
initially developed to support empiric antibiotic therapy
but also addressed de-escalation strategies and targeted
antibiotic therapy when pathogens were identiﬁed in
microbiological diagnostics. The programme also incor-
porates educational aspects with tools and evidence
from the current medical literature to support recom-
mendations given. After the programme was ﬁnished
and released, it was introduced in every ICU of the
department, giving every staff member the opportunity
to be trained in the applications. The programme
included a contact link to communicate with the team
responsible for drafting the CDSS. Furthermore, one
physician provided telephone support. All queries were
immediately discussed in the team and, if deemed
relevant, incorporated into the decision pathways. One
full-time physician was responsible for changing the pro-
gramme, for example, if new drugs were available or
locally updated resistance was available during the course
of the study.
Data were collected in ﬁve predominantly surgical
ICU with altogether 61 beds at the Charité University
Hospital in Berlin, Germany, a tertiary medical care
centre with 3200 beds. In these ICUs there is constant
rotation with every physician working for at least 2 years.
In the beginning there is structured training that
includes the usage of the antibiotic CDSS. There is
always a well-trained senior together with a younger
doctor. Additionally, there is a consultant either in the
ward or reachable via phone, which is especially critical
during night shifts. This team provides 24/7 care for
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patients. During the study period, there was no restric-
tion of diagnostic procedures or choice of antibiotic
therapy for participating ICUs. Antibiotic therapy was
prescribed by the physicians in charge under approval
of the senior consultant. Most patients were admitted to
the ICU postoperatively from different surgical disci-
plines (abdominal surgery, cardiac surgery, neurosur-
gery, trauma surgery and gynaecology); other patients
included non-operative patients suffering from acute
respiratory distress syndrome. For this study we included
every consecutive patient older than 18 years of age with
a length of stay in the ICU >48 h.
MEASUREMENTS AND DATA
Patient data were collected directly into electronic case
report ﬁles for each treatment day in the ICU. Data on
gender, age, medical history including substance abuse,
surgical procedures, length of stay and mode of dis-
charge (intensive care, intermediate care, normal care
or death), vital signs, laboratory ﬁndings, microbio-
logical and radiological diagnostics, and anti-infective
therapy were obtained. To ensure data consistency, study
data were re-evaluated in the middle and at the end of
each collection period. ICU scores (SOFA and SAPS II),
which are assessed regularly in the participating ICUs,
were also documented. Additionally, infection status and
the supposed or known focus of infection were documen-
ted daily. Immunosuppression was deﬁned as receiving
immunosuppressive medications such as corticosteroids
above the Cushing level, immune suppressive agents,
monoclonal antibodies or chemotherapy within the past
6 weeks. Microbiological ﬁndings were grouped by fungal
pathogens, Gram-positive and Gram-negative pathogens
and pathogens with enhanced resistance patterns. The
latter included intrinsic resistances as well as acquired
resistances, which are known to be more difﬁcult to treat.
CALCULATION OF THE ADHERENCE RATE
At the end of each evaluation period a team of infec-
tious disease and critical care specialists assessed the
antibiotic therapy in terms of guideline adherence. To
justify infection management, diagnostic investigations
Figure 1 Presentation of different user interfaces in the computerised decision support program (available at http://www.dgai-
abx.de/en/). (A) Summary of infection characteristics; (B) selection menu in the module resistance patterns and targeted therapy;
(C) selection menu in the antibiotic agents module. BAL, bronchoalveolar lavage; CPIS, Clinical Pulmonary Infection Score;
MRSA, methicillin-resistant Staphylococcus aureus; VAP, ventilator-associated pneumonia.
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and antibiotic therapy of suspected or known infection
were compared with guideline recommendations.15 An
ICU day was deﬁned as discrepant from guidelines if
one or more of the following criteria were identiﬁed:
(A) disregarding drug history (eg, starting an antibiotic
therapy for a new infection using the same agent that
has recently been given to this patient); (B) insufﬁcient
diagnostic measurements (eg, no microbiological
samples before start of antibiotic therapy, or no X-ray
before starting a treatment of suspected pneumonia);
(C) delayed antibiotic therapy (eg, documentation of
infection with accidental delay of empirical antibiotic
therapy); (D) unsuitable combination therapy (eg, com-
bination of two β-lactam antipseudomonal antibiotics);
(E) omission of combination drug (eg, inappropriate
coverage in patients with increased methicillin-resistant
Staphylococcus aureus risks); (F) antibiotic therapy in
patients without signs of infection (eg, prolonging anti-
biotic prophylaxis or treating SIRS with no signs of infec-
tion) or (G) continuing empirical broad spectrum
coverage without antibiotic de-escalation in patients with
documented pathogen detection causative for infection.
If the physician who cared for the patients on the ICUs
had documented a justiﬁcation for non adherence, the
day was counted as adherent.
After the initial evaluation, data were audited by
experts independent from the study team. The expert
team was unblinded to the patients and the data collect-
ing part of the study but blinded to the evaluation of
the adherence rating of the study team. The members
Figure 1 Continued.
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of the expert team had open access to every patient’s
data ﬁle and were able to randomly scrutinise the data
and evaluate the adherence independently from the
study team. The decision of the expert team was deter-
mining. None of the persons evaluating adherence were
involved in decision-making on the ward at any time for
any patient.
To calculate adherence rates, each treatment day
during the study period was recorded and evaluated as
described in detail elsewhere.16 Brieﬂy, the binary vari-
able of daily adherence was transferred into a relative
per-patient variable of guideline adherence by dividing
the cumulative number of days with guidelines conform-
ity by the patient’s total number of ICU days. The result-
ing variable represents a summary of therapy quality
throughout the ICU stay and has previously been found
to be related to outcome.16
END POINTS
The primary end point is guideline adherence over
5 years. Since resistances change over time, guidelines
could be modiﬁed during each evaluation period if new
microbiological ﬁndings became available.
For the evaluation of all-cause ICU mortality, patients
were followed until ICU discharge. The patient sample
was dichotomised based on a clinically relevant thresh-
old of 70% adherence rate to assess the association of
ICU mortality and quality of guideline adherence.
Outcomes in patients with high guideline adherence
rates of at least 70% were compared to those with lower
adherence rate. The cut-off of 70% was selected because
it is the quality indicator for ICU implementation rate of
our certiﬁed institutional quality management according
to DIN EN ISO 9001:2000 standard. This cut-off was also
taken because 70% accounts for a sufﬁcient ﬁrst step in
the meaning of improving guideline adherence accord-
ing to the literature and has been published by our
working group as having inﬂuence on the outcome of
ICU patients.15–18
STATISTICS
All statistical analyses were performed with PASW V.19
(SPSS Inc, USA). Categorical data are displayed as abso-
lute and relative values. Fisher’s exact and χ2 tests were
applied for statistical hypothesis testing of categorical
variables. Continuous data are displayed as means and
consecutive SD or median and quartiles depending on
their distribution. The Kruskal-Wallis tests and analyses
of variance were performed for continuous data accord-
ingly. The signiﬁcance level was deﬁned as a two-sided
p<0.05 for all tests.
Variables were additionally evaluated using multivari-
ate logistic regression analyses. For this, we ﬁrst exam-
ined those factors that were clinically important in
univariate analysis focusing on long-term effect of the
intervention (study groups pre vs post3). In the consecu-
tive regression model, all parameters were entered that
showed a signiﬁcant difference in the univariate analyses
resulting in seven factors (surgical patient, pre-existing
pulmonary disease, chronic liver disease and kidney
failure, diabetes mellitus, psychiatric disease and guide-
line adherence). In a second regression analysis on ICU
mortality, we also used this approach and evaluated base-
line characteristics in regard to the interesting factor of
high versus low guideline adherence; the consecutive
regression analysis had to include eight factors (age,
immune suppression, infection of bones or joints, soft
tissue infection, unknown focus of infection, fungal
infection, detection of multidrug resistant pathogens
and guideline adherence).
ETHICS AND DATA SAFETY
The institutional review board waived the need for
informed consent owing to the observational character
of the study.
RESULTS
Patient and basic characteristics
A total of 1395 patients were treated during the study
period. After exclusion of patients with treatment in ICU
of less than 48 h, 1316 patients were included in present
analysis. Basic characteristics are shown in table 1. Patients
included during the four evaluation periods were compar-
able; however, differences were seen in the distribution of
age, gender and pre-existing conditions. An increase of
concomitant pulmonary disease and chronic kidney
failure over time was noted. Pneumonia and abdominal
or surgical site infections accounted for most ICU infec-
tions observed.
Primary endpoint: adherence to locally adapted guidelines
Adherence to guidelines was 61.4±37% in the pre
period. Guideline adherence increased signiﬁcantly to
92±19% in post1 (pre/post1 p<0.001). It then decreased
to 76.3±30.7% (post1/post2 p<0.001) and remained
constant at 71.1±34.0% in post3 (post2/post3 p=0.178,
pre/post 3 p=0.001). Thus, a net increase of 10% guide-
line adherence was observed during the 5-year observa-
tion period. Figure 2 shows the guidelines adherence in
connection with the antibiotic free days.
Confounder analysis in the relationship of guideline
adherence and study periods
The validation of the primary endpoint, guideline
adherence, between pre and post3 is shown in table 2.
The following variables were included in a logistic
regression analysis as independent variables based on
baseline characteristics: surgical patient, pre-existing pul-
monary disease, chronic liver disease and kidney failure,
diabetes mellitus, psychiatric disease and guideline
adherence. After including these variables, the positive
association between guideline adherence and time
period (pre vs post3) remained statistically signiﬁcant
with an adjusted OR of 1.905 (1.359 to 2.669; p<0.001).
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Secondary end points
Measures of clinical performance and differences in anti-
biotic therapy are shown in table 3. Notably, antibiotic-free
days (AFD) increased over time starting from 30% of all
ICU days (pre) to 32% (post1), 46% (post2) and ﬁnally
achieving 42% (post3), with a corresponding p<0.01
over all time periods.
Mortality and confounder analysis in the relationship of
mortality and guideline adherence
Mortality during each evaluation period was lower for
patients with guideline adherence above 70%. Of 471
patients with an adherence less than 70%, 58 died
(12.3%) compared with 68 of 845 with an adherence
greater than 70% (8%; p=0.014). Based on this model,
guideline adherence remained statistically signiﬁcant
associated with ICU mortality with an adjusted OR of
1.556 (95% CI 1.05 to 2.31; table 4).
DISCUSSION
Adherence to locally adapted guidelines increased fol-
lowing implementation of a CDSS. Meaningful
improvement in adherence was observed at 5 years
without any further measures or interventions.
Antibiotic-free days increased accordingly and lower
mortality was found in patients with guidelines adher-
ence above 70%.
Although some of the sample characteristics varied
throughout the evaluation periods during this study,
these variations were not unexpected, based on previous
studies.19 For instance, the prevalence of pre-existing con-
ditions changed over the 5-year course of this study with
increased rates of concomitant pulmonary diseases and
chronic kidney failure over time. This is consistent with
other reports that the number of chronically ill patients
increases over time.20 Distribution of infections showed
signiﬁcant variation between the four evaluation periods.
Since infections are dependent on different factors, this
may be due to seasonal changes or a random spread.
After adjusting for potential confounders in a multivari-
able regression model including relevant factors, guide-
line adherence was higher in the postintervention
periods independent of other pre-existing conditions.
Guideline adherence was highest in the period dir-
ectly after implementation of the CDSS. Analysis for











Age in years median (25–75%Q) 66 (51–75) 67 (53–74) 62 (51–72) 64 (51–72,5) 0.031
Females (%) 138 (42.1%) 137 (44.1%) 153 (39.8%) 137 (46.8%) 0.321
Initial SAPS median (25–75%Q) 34.5 (25.3–44) 37 (28–48) 35 (24–48.8) 36 (25.5–49) 0.179
Initial SOFA median (25%–75%Q) 4 (2–7) 5 (3–7) 4 (1–8) 5 (1.5–8) 0.118
Comorbidities n (%)
Immune suprressioni 37 (11.3%) 11 (3.5%) 22 (5.7%) 29 (9.9%) <0.01
Cardiovascular 148 (45.1%) 143 (46%) 147 (38.3%) 150 (51.2%) 0.009
Pulmonary 35 (10.7%) 40 (12.9%) 79 (20.6%) 66 (22.5%) <0.01
Chronic liver disease 17 (5.2%) 25 (8.0%) 42 (10.9%) 36 (12.3%) 0.007
Chronic kidney failure 58 (17.7%) 45 (14.5%) 84 (21.9%) 80 (27.3%) 0.001
Metabolic disease 169 (51.5%) 123 (39.5%) 142 (37%) 123 (42%) 0.001
Psychiatric disease 75 (22.9%) 48 (15.4%) 24 (6.2%) 35 (11.9%) <0.01
Surgical vs medical (%) 278 (84.8%) 252 (81%) 282 (73.4%) 223 (76.1%) 0.001
Infections n (%)*
Pneumonia 117 (35.7%) 92 (29.6%) 131 (34.1%) 94 (32.1%) 0.387
Abdominal infections 44 (13.4%) 22 (7.1%) 33 (8.6%) 24 (8.2%) 0.037
Urinary tract infections 29 (8.8%) 28 (9%) 23 (6%) 20 (6.8%) 0.346
Bone or joint infections 16 (4.9%) 2 (0.6%) 10 (2.6%) 7 (2.4%) 0.009
Endocarditis 7 (2.1%) 8 (2.6%) 10 (2.6%) 5 (1.7%) 0.897
Wound and soft tissue 90 (27.4%) 32 (10.3%) 17 (4.4%) 8 (2.7%) <0.01
Meningoencephalitis 9 (2.7%) 1 (0.3%) 18 (4.7%) 9 (3.1%) 0.002
Bacteraemia 23 (7%) 26 (8.4%) 27 (7%) 20 (6.8%) 0.879
No focus specified 27 (8.2%) 29 (9.3%) 9 (2.3%) 24 (8.2%) <0.01
Catheter associated 7 (2.1%) 15 (4.8%) 3 (0.8%) 12 (4.1%) 0.003
Pathogens
Clostridium difficile infections 3 (0.9%) 2 (0.6%) 10 (2.6%) 6 (2%) 0.138
Fungi 61 (18.6%) 50 (16.1%) 46 (12%) 61 (20.8%) 0.012
Multidrug resistant pathogens 42 (12.8%) 27 (8.7%) 32 (8.3%) 34 (11.6%) 0.155
*Owing to occurrence of more than one infection per patient and polymicrobial infections, the detection of more than one pathogen is
possible.
iImmunosuppressive medications like corticosteroids above cushing level, immune suppressive agents, monoclonal antibodies or
chemotherapy within the last 6 weeks.
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confounders with univariate logistic regression illustrated
that although all relevant variables inﬂuenced the
primary end point, adherence to guidelines remained
signiﬁcant on its own. The model showed that the likeli-
hood of having higher guideline adherence in the
period post3 was still high and not due to a different
health status. Guideline adherence decreased initially
after the implementation period but remained stable
above a critical value of 70%, which is a well-accepted
value for guideline adherence.16–18 The level of guide-
line adherence observed in this study is in line with
other studies of antibiotic prescribing employing a
similar persuasive methodology.21 Interestingly, after an
initial peak in guideline adherence, the long-term
adherence in our study remained high compared with
the preinterventional period. By contrast, previous
studies of efforts to improve guideline adherence have
shown that the effect of such interventions is often
short-lived. For instance, Ferrer et al8 were able to show a
signiﬁcant increase in guideline adherence after an
extensive educational programme; however, without any
further intervention the adherence rate 1 year later had
fallen nearly to the baseline level. The sustained
improvement in guideline adherence observed in our
study may be due in part to the process of developing
the CDSS, which actively involved ward physicians as a
target user group. Similarly, previous studies of quality
indicators have shown that implementation works best if
front-line staff are involved in the development
process.22 One favourable point in our preparation of
the locally adapted guidelines is that it helps to over-
come a ‘prescribing etiquette’ and the social interfer-
ences with reasonable prescriptions described very
recently by Charani and colleagues.23 24 By including a
clinical hierarchy into the preparation and giving the
tool to junior doctors, overall compliance was enhanced;
however, we did not address reasons for the higher com-
pliance in speciﬁc populations. This suggestion is sup-
ported by the meta-analysis by Davey et al,7 who contend
that after the initial beneﬁt of restrictive measures, the
effects of persuasive interventions, such as ours, are sufﬁ-
cient to keep compliance high. Another advantage is
that the computer-based design is well suited to the
demands of evidence-based care by keeping doctors
abreast of current ﬁndings and relevant prescribing
information, which are otherwise difﬁcult to address in
the clinical workﬂow.25
Guidelines adherence is a process parameter and does
not provide a sufﬁcient measure of the quality of care
on its own. Dangers associated with the overuse of anti-
biotics are well recognised,12 and one objective of anti-
microbial stewardship programmes is to reduce
unnecessary use of antibiotics.7 In our data set, the
number of AFD increased over time. Thus, our data
suggest that an individual patient receives shorter
courses of antibiotics as guideline adherence increases.
This is in line with previous ﬁndings that a CDSS can
decrease antibiotic usage.26 The use of antibiotics in the
post1 period did not fall as much as anticipated in light
of the high percentage of adherence. It appears that
more time was needed to change the minds of doctors
in the ward, as evidenced by the continued increase in
ADF over the 5-year observation period. This hypothesis
is supported by Samore et al27 in a study of a CDSS on
the ambulant prescribing of antibiotics. They found a
signiﬁcant reduction in overall antibiotic use and
improved appropriateness of antibiotic selection was
observed after CDSS implementation. This group also
described that although the rate of prescription did not
change much in the ﬁrst year following the introduction
of a CDSS, adequacy did improved. In the second year,
they found a decrease in the prescription rate, which
translated into a decrease in unnecessary use.27
Unfortunately, this study lacked long-term follow-up;
thus, no conclusions may be drawn about the sustained
effects of those measures. Evans et al13 were able to show
Figure 2 Adherence to guideline and percentage of
antibiotic free days over study periods. MSSA,
methicillin-susceptible Staphylococcus aureus; MRSA,
methicillin-resistant Staphylococcus aureus; S. epidermidis
Staphylococcus epidermidis.
Table 2 Logistic regression analysis of the relationship




OR (95% CI) p Value
Surgery 0.608 (0.396 to 0.932) 0.023
Chronic pulmonary
disease
2.362 (1.462 to 3.816) <0.001
Chronic liver disease 3.035 (1.564 to 5.890) 0.001
Chronic kidney failure 1.634 (1.068 to 2.500) 0.024
Metabolic disease 0.643 (0.454 to 0.909) 0.012
Psychiatric disease 0.382 (0.237 to 0.616) <0.001
Guideline adherence 1.905 (1.359 to 2.669) <0.001
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that after the introduction of a CDSS, patients received
fewer antibiotics and had a shorter duration of antibiotic
therapy. However, this study also only had a 2-year obser-
vation period.
Mortality persisted at the same level throughout our
study despite the higher rates of pre-existing conditions
(eg, greater comorbidity) in the later evaluation periods.
To assess impact of guideline adherence on outcome, a
70% cut-off was chosen as ﬁrst target for adherence to
guideline.16 18 We would like to consider this threshold
only as a ﬁrst barrier in change management as it obvi-
ously does not reﬂect the adherence rate that should be
achieved in the long run. Nevertheless, mortality for
patients with an adherence above 70% was lower than
for patients with lower adherence rates. This association
persisted after adjusting for baseline characteristics, thus
validating the role of guidelines adherence in reducing
mortality. Similarly, previous studies showed that inad-
equate initial antibiotic therapy leads to excessive mor-
tality.5 This is mainly caused by emerging resistances as a
result of inadequate and unnecessary use of antibiotics,
and is exacerbated by the lack of development of new
antibiotic substances.28
LIMITATIONS
We believe that a randomised controlled trial would not
be a feasible design, since following guidelines is crucial
for the outcome and it would be unethical to restrain
adequate therapy from control group patients. In
concordance to the conclusions of Sintchenko et al,29 a
preinterventional and postinterventional design is the
best available for this research question. On the other
hand, this design is limited in inferring on causalities, as
other factors might have inﬂuenced the results. In this
context, we aimed to carefully assess for potential con-
founders but we could only control for a deﬁned set of
observed variables. For this study, external validity is
restricted mainly to the postoperative setting. Also, our
recommendations are locally adapted and results of this
single centre study in a tertiary university hospital might
not be transferable to other settings with its speciﬁc
decision-making structure. Another potential limitation
is related to the unblinded nature of this study. To
control at least partially for this effect, a team consisting
of a senior consultant and two assistants evaluated the
data for adherence. To further control for bias, an
expert team randomly scrutinised the data for the
results of the study team that was blinded, and had
the ﬁnal decision. Although there is some evidence in
the literature that a cut-off for adherence of 70% might
be a ﬁrst pragmatic barrier in change management17 18
associated with improved patient outcome,16 30 in the
long run adherence rates of >95% should be targeted to
optimise quality of treatment.
CONCLUSION
To the best of our knowledge, this is the ﬁrst study to
show improved long-term guideline adherence following
the implementation of a CDSS. Adherence rate at
5 years remained above a level of 70%. Consequently, we
are able to show that CDSS seems to have a lasting
beneﬁt, although physicians were only trained in the
beginning of the study. Improvement in guideline adher-
ence was paralleled by reductions in individual antibiotic
therapy. Furthermore, overall ICU mortality was asso-
ciated with guideline adherence further supporting the
role of CDSS in improving the quality of care.
Success of this implementation is probably due to
the multidisciplinary front-line team that developed the
CDSS, which included all disciplines involved in the
decision-making process in the ICU. One key advantage
of this programme is that, with help of a special function,
it can easily be customised to meet the needs of any
intensive care facility and that it is available to any ward
with internet access. As one of the key components to
improving prescription patterns, CDSS may help to
develop sufﬁcient stewardship programmes in the future.
Table 3 Secondary end points
Pre Post1 Post2 Post3
Characteristics N=328 (24.9%) N=311 (23.6%) N=384 (29.2%) N=293 22.3(%) p Value
Length of ICU stay (days) 9.2±10.7 9.1±9.6 9.9±12.1 11.3±12.2 <0.01
Mortality (%) 34 (10.4%) 34 (10.9%) 32 (8.3%) 26 (8.9%) 0.624
Antibiotic-free days (%) 30±27 32±28 46±39 44±38 <0.01
Table 4 Logistic regression analysis of the relationship







Guideline low vs high
adherence
1.556 (1.047 to 2.314) 0.029
Age 1.028 (1.014 to 1.042) <0.001
Immune suppression 1.279 (0.652 to 2.509) 0.474
Bone or joint infection 1.168 (0.416 to 3.275) 0.768
Unknown focus 1.252 (0.659 to 2.376) 0.492
Soft tissue infection 1.023 (0.572 to 1.829) 0.939
Fungus 2.862 (1.864 to 4.394) <0.001
Multidrug resistant
pathogens
1.335 (0.769 to 2.318) 0.305
Hosmer and Lemeshow test. χ2 14.82; p=0.63.
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